论文部分内容阅读
目的观察恩替卡韦(ETV)治疗慢性重型乙型肝炎的疗效和安全性。方法121例慢性重型乙型肝炎患者随机分为两组。对照组50例,给予常规的综合治疗;治疗组71例,在常规综合治疗的基础上,加ETV 0.5 mg,每日1次口服。分别观察两组治疗前后肝功能和凝血酶原活动度(PTA)、血清HBVDNA水平变化及疗效。结果治疗组总有效率为77.8%,显著高于对照组的40.0%(P<0.01);治疗后30 d,与对照组比较,治疗组存活患者的总胆红素(TBil)显著降低,PTA显著升高,血清HBVDNA显著降低(均P<0.001)。结论ETV治疗慢性重型乙型肝炎有较好的疗效和安全性。
Objective To observe the efficacy and safety of entecavir in the treatment of chronic severe hepatitis. Methods 121 patients with chronic severe hepatitis B were randomly divided into two groups. The control group of 50 patients given conventional comprehensive treatment; treatment group of 71 patients, on the basis of conventional comprehensive treatment, plus ETV 0.5 mg, 1 day orally. The changes of liver function, prothrombin activity (PTA), serum HBVDNA level and therapeutic effect were observed before and after treatment in both groups. Results The total effective rate in the treatment group was 77.8%, which was significantly higher than that in the control group (40.0%, P <0.01). At 30 days after treatment, the total bilirubin (TBil) in the treated group was significantly lower than that in the control group Significantly increased serum HBVDNA significantly reduced (both P <0.001). Conclusion ETV treatment of chronic severe hepatitis B has a good effect and safety.